AstraZeneca
identifying new targets through enabled big data | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
16 of 86
Related slides by other companies
Exscientia
Results
March 2024
operating at the interface of human ingenuity and technology a | Exscientia
Onion
IPO
April 2021
advanced big data technology driving continual improvement | Onion
BenevolentAI
Investor Conference
January 2023
strategic validation successful collaboration with year target collaboration is delivering multiple novel targets for complex diseases with high unmet need separate data environment established to integrate data into a bespoke knowledge graph and teams working in close collaboration to explore identify and validate targets deal structure of license fee milestone payments and downstream royalties data generated via the collaboration enriches the benevolent platform five novel targets selected for portfolio to date initial deal focussed on chronic kidney disease idiopathic pulmonary fibrosis year collaboration expansion to include heart failure systemic lupus | BenevolentAI
BenevolentAI
Investor Conference
January 2023
the benevolent platform comprehensive data foundations biology hypothesis driven data foundations target identification | BenevolentAI
Other recent decks by AstraZeneca
See all presentations (31 decks)
Results
February 2025
Results
November 2024
Results
November 2024
Investor Event
September 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights